Investigational drug · Phase 3
DMX-200
Also called: Repagermanium
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for FSGS.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "DMX-200"
First trial start
2022
May 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DMX-200", any sponsor or status.
Conditions studied
As listed on its trial records.
- FSGS
Largest trials
Live from ClinicalTrials.gov: studies naming "DMX-200" as an intervention, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARBPivotal-lookingRecruiting
Dimerix Bioscience Pty LtdIndustry
NCT05183646 · 286 participants (planned) · Start May 30, 2022 · Primary completion Dec 2029
Drug: DMX-200; Placebo · For: FSGS
Sites: Birmingham, Alabama; Phoenix, Arizona; Loma Linda, California · 220 sites in all
University of SydneyAcademic, hospital or other
NCT05122182 · 49 participants · Start Jan 7, 2022 · Primary completion Aug 15, 2022
Drug: Candesartan Cilexetil; Repagermanium and 2 more · For: COVID-19; SARS-CoV2 Infection
Sites: Aligarh, India; Chandigarh, India; Guntur, India · 10 sites in all
Dimerix Bioscience Pty LtdIndustry
NCT03627715 · 45 participants · Start Nov 6, 2018 · Primary completion Jul 23, 2020
Drug: Propagermanium; Placebo · For: Diabetic Kidney Disease
Sites: Gosford, Australia; Liverpool, Australia; St Leonards, Australia · 13 sites in all
Dimerix Bioscience Pty LtdIndustry
NCT03649152 · 8 participants · Start Nov 8, 2018 · Primary completion Jun 16, 2020
Drug: Propagermanium; Placebo · For: Focal Segmental Glomerulosclerosis
Sites: Gosford, Australia; Liverpool, Australia; St Leonards, Australia · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- DMX-200 in Patients With Primary Focal Segmental Glomerulosclerosis: Results of the Phase 2 ACTION2 Trial.
Heerspink HJL, Fornoni A, Inker LA, et al. · Kidney Int Rep 2025
- Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.
O'Hara DV, Bassi A, Wilcox A, et al. · BMJ Open 2024
- Inhibitory effect of organogermanium compound 3-(trihydroxygermyl)propanoic acid on fructose-induced glycation of amino compounds.
Masaki M, Shimada Y, Takeda T, et al. · Carbohydr Res 2024
- Investigation of Strategies to Block Downstream Effectors of AT1R-Mediated Signalling to Prevent Aneurysm Formation in Marfan Syndrome.
Valdivia Callejon I, Buccioli L, Bastianen J, et al. · Int J Mol Sci 2024
- Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Lawler PR, Derde LPG, van de Veerdonk FL, et al. · JAMA 2023
- Organogermanium suppresses cell death due to oxidative stress in normal human dermal fibroblasts.
Takeda T, Doiyama S, Azumi J, et al. · Sci Rep 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.